Royalty Report: Drugs, Cancer, Disease – Collection: 240572

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 240572

License Grant
The Canadian Licensor hereby grants to Licensee an exclusive, worldwide, royalty-bearing license, including the right to grant sublicenses (which themselves may include the right to grant further sublicenses), under the Licensor Patent Rights, the Licensor Know-How and Licensor’s interest in the Joint Patents, to research, develop, make and have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Products in the Field.
License Property
Product means any member of the class of substituted 4-H chromenes, analogs and derivatives thereof and any compound encompassed by the generic chemical formulae included in those Joint Patent Rights specifically set forth below, including all formulations and modes of administration thereof.

Licensor Patent Rights means all Patents in any country within the Territory which are owned or Controlled by Licensor as of the Effective Date or during the term of this License Agreement that claim the manufacture, use or sale of a Product (including, without limitation, any formulation, process of manufacture, or method of use of such Product).  

Joint Patent Rights shall mean those Patents claiming inventions made jointly by one (1) or more employees or consultants of each Party or otherwise listed hereto.  Joint Patent Rights as they exist as of the Effective Date are set forth hereto.
Application Patents:
10/146,138 – SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
10/146,136 – Substituted  COUMARINS AND QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF

Patent (which term may be used either in the singular or plural form) means any patent and patent applications, and all additions, divisions, continuations, continuations in-part, pipeline protection, substitutions, reissues, extensions, registrations, patent term extensions, supplementary protection certificates and renewals of any of the above.

Field of Use
Patent relate to the MX2105 series of vascular targeting agent cancer drug candidates.

IPSCIO Record ID: 240463

License Grant
Licensor hereby grants to Canadian Licensee an exclusive, worldwide, royalty-bearing license, including the right to grant sublicenses (which themselves may include the right to grant further sublicenses), under the Licensor Patent Rights and Licensor Know-How to research, develop, make and have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Products in the Field.
License Property
Product means any member of the class of substituted 4-H chromenes, analogs and derivatives including all formulations and modes of administration thereof.  In addition, the Product as defined above shall also mean any further member of the broader class of substituted 4-H chromenes, analogs and derivatives as described in any claim of U.S. application no. 60/185,211 as filed that shall be included in the Research Program pursuant to this Agreement.

Patent (which term may be used either in the singular or plural form) means any patent and patent applications, and all additions, divisions, continuations, continuations in-part, pipeline protection, substitutions, reissues, extensions, registrations, patent term extensions, supplementary protection certificates and renewals of any of the above.

Licensor Patent Rights means all Patents in any country within the Territory which are owned or Controlled by Licensor as of the Effective Date or during the term of this Agreement that relate to, or are necessary or useful for the design, synthesis, identification, research, development, manufacture, use or sale of Products, including those Patents which claim a Product, formulation, process of manufacture, or method of use of such Product. Licensor Patent Rights include Dominated Patent Rights.  Dominated Patent Rights invented solely by employees or consultants of Licensee are referred to herein as Dominated Licensee Patent Rights.

Field of Use
Licensing agreement is for a series of anticancer compounds (CV2105).  CV2105 stimulates specific activity in caspases, enzymes that modulate and carry out the cellular signaling pathways involved in apoptosis.  CV2105 compounds have shown the potential to be effective where current chemotherapeutic compounds have not worked due to drug resistance. We believe that CV2105 may prove to provide a benefit to patients for whom their cancer therapy is currently impaired by such drug resistance.'

IPSCIO Record ID: 233475

License Grant
For the Exclusive License Grant, the Licensor of Scotland, operating in the United Kingdom, grants  an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How to develop, make, have made, use, import, offer for sale, market, commercialize, distribute and sell and otherwise dispose of Compound and Product in the Territory. The exclusive license granted includes the right to grant sublicenses.

And, for the Exclusive License Grant, Licensor grants an exclusive license to use and exploit the NOS Patent Assets and the Licensors NOS Know-How to develop, make, have made, use, import, offer for sale, market, commercialize, distribute and sell and otherwise dispose of the NOS Inhibitor Technology and any NOS Inhibitor and the Split Dose Patent Assets and the Licensors Split Dose Know-How to develop, make, have made, use, import, offer for sale, market, commercialize, distribute and sell and otherwise dispose of Compound or Product using the Split Dose Technology, each solely in connection with the use of Compound and/or Product in the Territory.  The exclusive license granted includes the right to grant sublicenses.

License Property
The rights are to a series of novel vascular targeting agents for cancer treatment from Licensor.  The targeting agents are known as the ANG-600 series.

The Product shall mean any product in final form for commercial sale by prescription, over-the-counter, or by any other method, or, where the context so indicates, the product being tested in clinical trials, which contains Compound as at least one of the therapeutically active ingredients, in all final dosage forms and package configurations for any indication, or any line extension thereof.

The Compound shall mean the chemical compounds known as benzimidazole carbamate class vascular targeting agents,including those designated ANG-600 Series, whose more specific chemical names are 5 (6) substituted benzimidazole-2-carbamates, and any derivative, homolog, analog or conjugate of any of the foregoing, and any isomer, salt, hydrate, solvate, metabolite, or prodrug or the like of any of the foregoing.

The NOS Inhibitor shall mean a chemical composition that inhibits the formation or action of nitric oxide, including those disclosed in the NOS Patent Assets.

NOS Inhibitor Technology shall mean technology relating to the combination of vascular targeting agents, including Compound, and an NOS Inhibitor, including the inventions disclosed in the NOS Patent Assets.

NOS Patent Assets shall mean United States and foreign patents and patent applications, which shall be deemed to include certificates of invention and applications for certificates of invention, which as of the Effective Date or at any time during the term of this Agreement:
– are owned by Llicensor (including Licensors interest in jointly owned patents and patent applications) or which Licensor through license or otherwise has or acquires rights, and
– relate to the combination with Compound or Product of an NOS Inhibitor or the NOS Inhibitor Technology including but not limited to methods of their manufacture, methods of their use, or otherwise relate to Licensor NOS Know-How, including all certificates of invention, divisions, continuations, continuations-in-part, reissues, supplementary protection certificates or the like of any such patents and current and future patent applications.

Split Dose Patent Assets shall mean United States and foreign patents and patent applications, which shall be deemed to include certificates of invention and applications for certificates of invention, which as of the Effective Date or at any time during the term of this Agreement:
– are owned by Licensor including Licensors interest in jointly owned patents and patent applications or which Licensor through license or otherwise has or acquires rights, and
– relate to the use of Compound or Product in divided doses including but not limited to methods of their manufacture, methods of their use, or otherwise relate to Licensor Split Dose Know-How, including all certificates of invention, divisions, continuations, continuations-in-part, reissues, supplementary protection certificates or the like of any such patents and current and future patent applications.

The Split-Dose Technology shall mean a method of administering any vascular damaging agent in a divided dose, including the inventions disclosed in the Split-Dose Patent Assets.

Field of Use
The application of the product is novel vascular targeting agents for cancer treatment.

IPSCIO Record ID: 282871

License Grant
Licensee and the Canadian Licensor amend certain provisions of the Agreement granted to include but not limited to milestone and royalty payments with respect to a Product being commercialized.
License Property
Product means any member of the class of substituted 4-H chromenes, analogs and derivatives thereof and any compound encompassed by the generic chemical formulae.
Field of Use
MX2105 series of vascular targeting agent cancer drug candidates.

IPSCIO Record ID: 291164

License Grant
The licenses granted include the right of each licensee to use its Affiliates in exercising such rights and carrying out its obligations under this Agreement.

Licensor hereby grants to Licensee the exclusive (except as to Licensor to permit it conduct its Co-Funded Development and/or Co-Commercialization activities and those activities under the ITMN-191 Transition Plan hereunder) license under the Licensor Know-How and Licensor Patent Rights and under Licensor’s rights in Joint Know-How and Joint Patent Rights to develop, make, have made, use, import, export, offer for sale and sell Licensed Compounds and Products in the Territory.

License Property
ITMN-191 shall mean that Macrocycle identified within Licensee as ITMN-191, together with its salts and esters, which is hereby designated a Licensed Compound.

Macrocycle shall mean any cyclic macromolecule in the Field containing a substituted proline moiety and optional Pl and P3 groups as part of the backbone ring and supporting the attachment of Pl and P4 groups.

Licensee Patent Rights shall mean any and all patents and patent applications in the Field in the Territory which are Controlled by Licensor during the term of this Agreement which Cover any activity permitted under this Agreement, all to the extent that the subject matter claimed therein is used in the course of performing any activity permitted under this Agreement, including, but not limited to, the making, using, selling, offering to sell, exporting or importing Lead Compound, Licensed Compounds, Products, Passed Compounds or Reverted Compounds. For the purposes of this Agreement, “patents and patent applications” shall be deemed to include certificates of invention and applications for certificates of invention, as well as divisions, continuations, continuations-in-part, reissues, renewals, extensions, supplementary protection certificates, and the like of any such patents and patent applications and foreign equivalents thereof.

Joint Patent Rights shall mean any and all patents and patent applications in the Field in the Territory which are invented jointly during the term of this Agreement by employees of both Parties according to the U.S. laws pertaining to joint inventorship. For the purposes of this Agreement, “patents and patent applications” shall be deemed to include certificates of invention and applications for certificates of invention, as well as divisions, continuations, continuations-in-part, reissues, renewals, extensions, supplementary protection certificates, and the like of any such patents and patent applications and foreign equivalents thereof.

Licensed Compound shall mean (a) ITMN-191 and (b) Collaboration Compounds properly included by Licensee as Licensed Compounds; provided however, Licensee may substitute a Lead Compound for an existing Licensed Compound as set forth in this Agreement; provided further there shall not be more than two (2) Licensed Compounds at any time during the Term unless Licensee shall have exercised its option to expand the number of Licensed Compounds pursuant to this agreement.

Product(s) shall mean any pharmaceutical preparation containing a Licensed Compound for any and all uses in humans, including any Combination Product.

Field of Use
Field shall mean the treatment and/or prevention of acute or chronic HCV infection in humans by administering a compound whose mechanism of clinical activity results solely from  binding to and inhibiting the serine protease active site of HCV NS3/4A.

IPSCIO Record ID: 282838

License Grant
Licensor hereby grants to Licensee and its Affiliates an exclusive license, with the right to sublicense, under the Licensor Technology to make, have made, use, sell, offer for sale, import, and export Products in the Field in the Territory.
License Property
Licensor has developed and owns or controls certain intellectual property rights with respect to a controlled release formulation of anagrelide.

Licensor Patents means (a) those Patents set forth hereto (the Initial Licensor Patents); (b) any other Patents owned, licensed, or controlled by Licensor or any Affiliate thereof, or subject to an obligation of assignment to Licensor or any Affiliate thereof, Covering or relating to any portion of the Technology; (c) any additions, divisionals, continuations, continuations-in-part, conversion, supplemental examinations, extensions, term restorations, registrations, re-instatements, amendments, reissuances, corrections, substitutions, re-examinations, registrations, revalidations, supplementary protection certificates, renewals, and foreign counterparts of the Initial Licensor Patents or the Patents described in (b) above, and any other Patents owned, controlled, or licensed by Licensor claiming priority to any of the foregoing or any of the Patents referenced in clause (a) or (b) above; and (d) all patents issuing from any of the Patents mentioned in clause (a), (b), or (c) above and any foreign counterparts of any such Patents, and which shall include, in any case, patents surviving post grant review and inter partes review.

US patent 6,585,995  Methods and compositions for treating platelet-related disorders
US Patent Application 20130022671

Product means a product that is Covered by one or more Licensor Patents in any country in which such product or any part thereof is made, used, or sold.

Licensor Technology means the Licensor Know-How and the Licensor Patents.

Patent(s) means any granted or issued patents and pending patent applications, together with all additions, divisionals, continuations, continuations-in-part, substitutions, reissues, re-examinations, supplemental examinations, patents reviewed under post grant review or inter partes review, extensions, registrations, patent term extensions, revalidations, supplementary protection certificates, and renewals of any of the foregoing, and all foreign applications and patents corresponding to or claiming priority from any of the foregoing.

Field of Use
GALE-401 contains the active ingredient anagrelide, an FDA-approved product, which has been in use since the late 1990s for the treatment of essential thrombocythemia (ET).

Essential thrombocythemia (ET) is a rare chronic blood cancer (myeloproliferative neoplasm) characterised by the overproduction of platelets (thrombocytes) by megakaryocytes in the bone marrow.

Cardiovascular Field means the direct prevention, treatment, diagnosis of myocardial infarction, strokes and peripheral arterial disease in humans or other animals. For sake of clarity the Cardiovascular Field will not include the prevention, treatment or diagnosis of conditions that may ultimately lead to a decrease in the risk of thrombotic events, such as Myeloproliferative Disorders and other hematological indications.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.